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Abstract
Adrenocortical carcinoma (ACC) is an aggressive tumor showing frequent metastatic spread and
poorsurvival.Althoughrecentgenome-widestudiesofACChavecontributedtoourunderstanding
of the disease, major challenges remain for both diagnostic and prognostic assessments. The
aim of this study was to identify speciﬁc microRNAs (miRNAs) associated with malignancy and
survivalofACCpatients.miRNAexpressionproﬁlesweredeterminedinaseriesofACC,adenoma,
and normal cortices using microarray. A subset of miRNAs showed distinct expression patterns in
theACCcomparedwithadrenalcorticesandadenomas.Amongothers,miR-483-3p,miR-483-5p,
miR-210, and miR-21 were found overexpressed, while miR-195, miR-497, and miR-1974 were
underexpressedinACC.InhibitionofmiR-483-3pormiR-483-5pandoverexpressionofmiR-195or
miR-497 reduced cell proliferation in human NCI-H295R ACC cells. In addition, downregulation
of miR-483-3p, but not miR-483-5p, and increased expression of miR-195 or miR-497 led to
signiﬁcant induction of cell death. Protein expression of p53 upregulated modulator of apoptosis
(PUMA), a potential target of miR-483-3p, was signiﬁcantly decreased in ACC, and inversely
correlated with miR-483-3p expression. In addition, high expression of miR-503, miR-1202, and
miR-1275 were found signiﬁcantly associated with shorter overall survival among patients with
ACC(Pvalues:0.006,0.005,and0.042respectively).Insummary,weidentiﬁedadditionalmiRNAs
associated with ACC, elucidated the functional role of four miRNAs in the pathogenesis of ACC
cells, demonstrated the potential involvement of the pro-apoptotic factor PUMA (a miR-483-3p
target) in adrenocortical tumors, and found novel miRNAs associated with survival in ACC.
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Introduction
Patientswithtumorsoftheadrenalcortexmaypresentan
incidentally detected or hormonally overproducing
adrenocortical adenoma, or uncommonly an adrenocor-
tical carcinoma (ACC). ACC is an aggressive tumor
associated with poor prognosis in adults (Bertherat et al.
2006).DifferentialdiagnosisbetweenACCandthemore
commonadenomaisdifﬁcult,particularlyforthe tumors
in the marginal category, i.e. Weiss score 2 or 3 vs 4.
Moreover, prognostic tools for early recognition of
metastatic ACC disease and adverse outcome are
presently lacking in routine diagnostics. Proﬁlings of
mRNA and microRNA (miRNA) expressions in human
cancer have revealed important alterations that do not
only have possible diagnostic and prognostic value but
also point toward molecular alterations of mechanistic
importance for tumor etiology and progression.
In adrenocortical tumors, mRNA expression proﬁ-
lings by several independent groups have revealed
signiﬁcant and reproducible alterations for the
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determination of ACC prognosis (Giordano et al.
2003, de Fraipont et al. 2005, Velazquez-Fernandez
et al. 2005, Giordano et al. 2009, Laurell et al. 2009,
de Reynies et al. 2009, Soon et al. 2009a). One of the
most striking ﬁnding was the signiﬁcant overexpres-
sion of insulin-like growth factor 2 (IGF2) in ACC,
which was observed in O80% of cases compared with
adrenal cortices and hormonally active/inactive ade-
nomas (Giordano et al. 2009, Laurell et al. 2009,
de Reynies et al. 2009). In addition, the expression
levels of other genes such as DLG1 and PINK1 have
been associated with the clinical outcome of ACC
(de Reynies et al. 2009).
miRNAs are w22 nucleotide long single-stranded
non-coding RNAs generated by the RNase-III
enzyme Dicer from endogenous hairpin-shaped
transcripts (Iorio & Croce 2009). miRNAs have
diverse roles in many biological processes and have
also been shown important for tumor development,
by acting as oncogenic or tumor suppressive species.
Besides, accumulating evidence also supports a role
of miRNAs as diagnostic and prognostic biomarkers
of human cancers (Iorio & Croce 2009, Ferracin
et al. 2010). Proﬁlings of adrenocortical tumors have
identiﬁed several deregulated miRNAs in benign
adrenocortical diseases (Iliopoulos et al. 2009,
Bimpaki et al. 2010), as well as ACC (Soon et al.
2009b, Tombol et al. 2009, Doghman et al. 2010,
Patterson et al. 2011). Several deregulated miRNAs
have been reported in ACC, including overexpression
of miR-483-3p and miR-483-5p, which are tran-
scribed from an intronic sequence of the IGF2
gene (Soon et al. 2009b, Doghman et al. 2010).
miR-483-3p has recently been shown to target the
pro-apoptotic gene BCL-2-binding component 3/p53
upregulated modulator of apoptosis (BBC3/PUMA)
in cancers of the colon, liver, and breast (Veronese
et al. 2010), suggesting its anti-apoptotic role in a
variety of tumor types.
In this study, we characterized miRNA expression
patterns of ACC compared with adenomas and normal
adrenal cortices, and related the ﬁndings to outcome
at follow-up. The functional consequences of
miR-483-3p, miR-483-5p, miR-195,a n dmiR-497
deregulations were studied in vitro concerning cell
proliferation and apoptosis. We further explored the
involvement of PUMA, a potential target of miR-483-3p,
in clinical samples. Our ﬁndings may contribute to
further understanding of ACC development, and
suggest a role for selected miRNAs as diagnostic
and prognostic biomarkers in ACC.
Materials and methods
Tumors and normal tissues
A total of 68 snap-frozen primary sporadic adrenocor-
tical tumors collected at the Karolinska University
Hospital were included in this study. In addition,
histopathologically veriﬁed normal adrenal cortical
samples were obtained from ten patients undergoing
nephrectomy for other reasons and used as non-
neoplastic reference tissues. All samples were obtained
with informed consent and the study of the tissue
materials was approved by the Local Ethics Committee.
Tumors were diagnosed following the WHO classi-
ﬁcation(DeLellisetal.2004 )asadrenocorticaladenoma
(Ad 1–43) or ACC (Ca 1–25). Clinical details have been
partly published for subsets of the cases in previous
studies (Laurell et al.2 0 0 9 ). All 25 carcinoma cases
were followed-up until May 2011 or until their death,
and the follow-up data is detailed together with clinical
and histopathological information in Supplementary
Table 1, see section on supplementary data given at the
end of this article. Thirteen of the 43 adenoma cases
were cortisol-producing tumors (Cushing) from one
male and 12 female patients with a mean age of
diagnosis at 56 years (range 27–81) and a mean tumor
size of 3.8 cm (range 1.5–6.5). Sixteen adenomas were
aldosteronomas (ﬁve male and 11 female patients) with
a mean age of 46 years (range 16–79) and a mean tumor
size of 2.0 cm (range 0.9–4.7). The last 14 adenomas
were classiﬁed as incidentalomas (six male and eight
female patients) with a mean age of 59 years (range
42–65) and a mean size of 3.9 cm (range 2.5–5.3). The
median follow-up time for adenomas was 39 months
(range 12–258). At the end of the follow-up, no
adenoma patient had disease progression or metastasis.
Cell line
The ACC cell line NCI-H295R was purchased from
the American Type Culture Collection (ATCC#
CRL-2128; LGC Standards, Middlesex, UK). Cells
were maintained in DMEM:F12 medium containing
2.5% of NuSerum (cat. no. 355500; BD Biosciences,
Bedford, MA, USA), 1% penicillin/streptomycin and
1% insulin-transferin-sodium selenite (ITSC1) liquid
media supplement (cat. no. I2521; Sigma–Aldrich
Logistik GmbH) at 37 8C and 5% CO2. Authentication
of the cell line was evaluated and veriﬁed by Bio-
Synthesis, Inc. (Lewisville, TX, USA) employing
genotyping of 15 short tandem repeat (STR) loci and
the amelogenin gene (AMEL), and comparison with
genotype information at the ATCC (Supplementary
Table 2, see section on supplementary data given at the
end of this article).
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Total RNA isolation was performed by mirVana
miRNA Isolation Kit (Applied Biosystems/Ambion,
Austin, TX, USA). Measurement of RNA concen-
trations was done using a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington,
DE, USA).
Microarray-based miRNA proﬁling
Global miRNA expression proﬁling of adrenocortical
tumors and normal cortices was performed by the
Human Agilent’s miRNA microarray system (Agi-
lent, Santa Clara, CA, USA) with probes matching
903 human miRNAs (miRBase release 14). Array
hybridizations and data analyses were performed
essentially as described previously (Caramuta et al.
2010). In brief, samples of 120 ng total RNA were
labeled with Cyanine 3-pCp, hybridized onto arrays
for 18–20 h at 55 8C, followed by washing. Slides
were scanned in an Agilent microarray scanner
G2565BA and images were processed with Feature
Extraction Software v10.7.3.1 (Agilent). Cluster 3.0
Software (http://bonsai.hgc.jp/~mdehoon/software/
cluster/) was used for normalization and median
centering (de Hoon et al. 2004). Normalized
miRNAs with !50% missing values were included
in subsequent analyses for hierarchical clustering and
signiﬁcance analysis of microarrays (SAM). The data
from microarray analysis have been deposited at
NCBI Gene Expression Omnibus (GEO accession
number, GSE22816).
QRT-PCR analysis of individual miRNAs
Selected mature miRNAs were quantiﬁed using
commercially available TaqMan qRT-PCR assays
(Applied Biosystems) and a 7900HT Real-Time
PCR System (Applied Biosystems). cDNA was
synthesized from 25 ng total RNA using TaqMan
mRNA RT Kit (Applied Biosystems) and used for qua-
ntiﬁcation of miR-483-3p (ID 002339), miR-483-5p
(ID 002338), miR-497 (ID 001043), miR-195 (ID
000494), miR-1974 (ID 121209_mat), miR-210 (ID
000512), miR-21 (ID 000397), miR-503 (ID 001048),
miR-1202 (ID 002858), miR-1275 (ID 002840),
miR-638 (ID 001582), miR-1915 (ID 121111_mat),
and miR-572 (ID 001614) with normalization against
RNU6B (ID 001093). All reactions were perfor-
med in triplicate, and relative expression levels were
determined with the DCT method and reported
as 2K DCT.
miRNA inhibition and overexpression in
NCI-H295R cells
NCI-H295R ACC cells were transfected using
Nucleofector Technology (Amaxa Biosystems,
Gaithersburg, MD, USA). In brief, 3!10
6 cells were
resuspended in 100 ml Nucleofector solution R, and
mixed with 100 pmol of miRNA inhibitors (anti-miR-
483-3p or anti-miR-483-5p; Applied Biosystems/
Ambion) or miRNA precursors (pre-miR-195 or
pre-miR-497; Applied Biosystems/Ambion). Anti-
miR-negative control #1 or pre-miR-negative control
#1 (Applied Biosystems/Ambion) containing a non-
targeting sequence molecule was used as a negative
control. Cells were then electroporated using the
program T-20, allowed to recover in DMEM:F12
media for 15 min at 37 8C and seeded in T-25 ﬂasks
with 5 ml DMEM:F12 media. Culture media was
replaced after 24 h and cells were cultured for
additional 72 h. All transfection experiments were
repeated at least three times and used for proliferation
and apoptosis assays. Transfection efﬁciency was det-
ermined by measuring the endogenous miR-483-3p,
miR-483-5p, miR-195,o rmiR-497 expression levels
by qRT-PCR (Supplementary Figure 1, see section
on supplementary data given at the end of this article).
To demonstrate that the transfected miRNAs achieved
physiologically relevant expression levels, we com-
pared the expression fold change differences between
the experimental cell culture systems (anti-miRNA/
pre-miR versus control) and the clinical materials
(carcinomas versus normal cortices) for miR-483-3p,
miR-483-5p, miR-195, and miR-497. In the transfected
cells expressing speciﬁc miRNA assayed, we observed
a reduction of w12-fold for miR-483-3p and approxi-
mately ninefold for miR-483-5p while we noticed
w15- and 30-fold increase for miR-195 and miR-497,
respectively, compared with the negative control.
The effect of transfections had a similar magnitude of
miRNA expression levels as for the comparison
between carcinomas and normal adrenal cortices.
In carcinomas, we observed an average increased
expression of 166-fold (range 0.1–1330) and 73-fold
(range 0.1–400) for miR-483-3p and miR-483-5p,
respectively; but a reduced expression of sixfold
(range 0.6–26) and 18-fold (range 0.3–170) for
miR-195 and miR-497 respectively.
Cell proliferation WST-1 colorimetric assay
WST-1 (4-(3-(4-iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio)-1,3-benzene disulfonate; cat. no.
11644807001; Roche Applied Science) colorimetric
assay was carried out to determine the effects of
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miR-497 overexpression on cell proliferation. The
assay was performed by 96-well plates, with seeding of
w20 000 cells in each well. After 72 h of transfection,
20 ml of the WST-1 solution were added to the culture
medium and incubated for 2.5 h at 37 8C. Absorbance
was subsequently determined using a microplate
ELISA reader (VERSAmax; Molecular Devices,
Sunnyvale, CA, USA) and analyzed with SoftMax
Pro 5 Software (Molecular Devices) applying the
wavelengths 450 nm for measurements and 650 nm as
reference. All experiments were conducted in eight
wells for each condition, and replicated at least three
times. Cell proliferation was calculated by comparing
the absorbance values of the samples after background
subtraction. The fraction of surviving cells was
calculated by deﬁning the anti-miR- (or pre-miR)-
negative control #1-treated cells as one.
Apoptosis caspase-3 colorimetric assay
The caspase-3 colorimetric assay (cat. no. L00289;
Genscript, Piscataway, NJ, USA) was used to evaluate
the effects of miR-483-3p and miR-483-5p inhibition
or miR-195 and miR-497 overexpression on apoptosis;
3!10
6 cells were transfected and seeded in T-25 ﬂasks.
After 72 h of transfection, proteins were isolated and
quantiﬁed by Bio-Rad Protein Assay (Bio-Rad). Fifty
microliters oflysatecontaining50 mgpr ot ei nwa smi xe d
with 50 mlo f2 ! reaction buffer and 5 mlo fc a s p a s e - 3
substrateandincubatedfor4 hat37 8C.Absorbancewas
subsequently determined using a microplate ELISA
reader (VERSAmax; Molecular Devices) and analyzed
with SoftMax Pro 5 Software (Molecular Devices)
applying the wavelengths 405 nm for measurement.
Apoptosis was calculated by comparing the absorbance
values of the anti-miR/pre-miR treated cells with the
respective negative control-treated cells. All the experi-
ments were replicated three times.
Western blot analysis
Whole cell lysates were prepared from normal and
tumortissue samplesbyhomogenization inNP-40lysis
buffer (cat. no. FNN0021; Invitrogen), with addition of
proteaseinhibitor(completeproteaseinhibitorcocktail;
Roche Diagnostics Corporation) and 1 mM of phenyl-
methanesulfonyl ﬂuoride (Sigma–Aldrich). After
quantiﬁcation by Bio-Rad Protein Assay (Bio-Rad),
60 mg of lysate was separated in Novex 10% Tricine
gels (Invitrogen) and transferred to nitrocellulose
membranes (LC2001; Invitrogen). Filters were blocked
with 5% non-fat milk diluted in TBS/0.05% Tween 20,
and incubated with rabbit polyclonal anti-PUMA
antibody (#4976, Cell Signaling Technology, Danvers,
MA, USA) at 1:1000 dilution, followed by an anti-
rabbit IgG–HRP (1:3000; #170-6515; Bio-Rad Labora-
tories) used as secondary antibody. Detection was
carried out with Novex ECL HRP chemiluminescent
substrate reagent (#WP20005; Invitrogen). Novex
Sharp Pre-stained protein standards (#57318; Invitro-
gen) and MagicMark XP (#LC5602; Invitrogen)
markers were used to determine relative molecular
weights. Protein levels were quantiﬁed on X-ray ﬁlms
from immunoblots using ImageJ Software (http://rsb.
info.nih.gov/ij/). Subsequent incubation of the ﬁlters
with an anti-GAPDH antibody (sc-47724; Santa Cruz
Biotechnology, Inc, Santa Cruz, CA, USA) diluted at
1:5000 was performed for normalization purposes.
Statistical analysis
All analyses were performed by Statistica 8.0 (StatSoft,
Inc., Tulsa, OK, USA) or MS Ofﬁce Excel 2007, unless
otherwise speciﬁed. Unpaired Student’s t-test was
conducted to compare miRNA expressions in different
groups, while paired Student’s t-test was performed to
analyze transfection experiments. Correlations between
miR-195 and miR-497,a n dmiR-483-3p and PUMA
expressionlevelswereassessedbyPearson’scorrelation
analyses and P values were estimated by permuting the
samples. SAM survival analysis was used to identify
miRNAs associated with survival. P values were
obtained for the Cox score statistics using the
c
2-distribution. For survival analysis, all patients who
died of unknown causes or causes unrelated to ACC
(i.e. Ca 3, Ca 7, Ca 12, and Ca 14) during follow-up
were considered as ‘censored’. Selected miRNAs
potentially associated with survival were analyzed by
TaqMan qRT-PCR and carcinoma patients were classi-
ﬁed into different groups with high or low expression of
each miRNA according to median level. The inter-
relationship of miRNAs with survival was studied using
Kaplan–Meier plots, and the curves for each group were
compared by log-rank test. All the analyses were two-
tailed and P values !0.05 were considered signiﬁcant.
Results
Deregulated miRNAs in ACC
In this study, we characterized miRNA expression
patterns in a cohort of 48 adrenocortical tumors (26
adenomas and 22 carcinomas) and four normal adrenal
cortices using a microarray-based approach. Unsuper-
vised clustering analysis classiﬁed the samples in
different subgroups based on the similarity of their
miRNA expression proﬁles. In Fig. 1, clustering based
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consisted of the majority of carcinoma samples (16 of
the 22 ACC; 72%) and cluster B comprised 19
adenomas and the remaining six carcinomas. Five of
the six ACC patients in cluster B are still alive at the
end offollow-up and one died of unrelated causes with
ACC after 65 months. All four normal adrenal cortices
were grouped in cluster C, and the remaining seven
adenomas were included in cluster D.
We also performed SAM analysis to identify the
most signiﬁcant deregulated miRNAs that could
distinguish carcinomas from adenomas and adrenal
cortices. The analysis identiﬁed 72 differentially
expressed miRNAs with a false discovery rate (FDR)
of 0% (Supplementary Table 3, see section on
supplementary data given at the end of this article).
Several of these miRNAs were also found to have
signiﬁcantly differential expression in the comparisons
between carcinomas and adenomas or normal adrenal
cortices (Supplementary Tables 4 and 5, see section on
supplementary data given at the end of this article). To
verify the signiﬁcance of the results obtained by
microarray analysis, we evaluated the expression
levels of seven miRNAs (miR-483-3p, miR-483-5p,
miR-210, miR-21, miR-1974, miR-195, and miR-497)
by qRT-PCR in a series of 68 adrenocortical tumors
Normal adrenal cortices
Adrenocortical adenomas
Adrenocortical carcinomas
+0.01
–0.01
0
Figure 1 Unsupervised clustering analysis of microarray-based miRNA expression data for four normal adrenal cortices (N),
26 adenomas (Ad), and 22 carcinomas (Ca). Samples were clustered using the Spearman rank correlation and complete linkage.
The four main clusters obtained (A–D) are indicated above the heatmap. Red and green colors indicate relatively high and low
expression respectively. Missing values are indicated in gray. *Alive;
†dead of disease;
#dead of unrelated or unknown causes.
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adrenal cortices (Fig. 2). These miRNAs were selected
among those with the highest score in the SAM
analysis, or because of their involvement in adrenal
cortical tumors or other tumor types. In concordance
with the microarray results, the qRT-PCR analyses
revealed signiﬁcantly higher expression of miR-483-
3p, miR-483-5p, miR-210, and miR-21, as well as lower
expression of miR-1974, miR-195, and miR-497 in
carcinomas compared with adrenal cortices or adeno-
mas (Fig. 2 and Supplementary Figure 2, see section on
supplementary data given at the end of this article).
Interestingly, two of these miRNAs, miR-483-3p and
miR-483-5p, were also signiﬁcantly differential
expressed between the carcinomas in cluster B and
cluster A observed in unsupervised clustering (Supple-
mentary Table 6, see section on supplementary data
given at the end of this article). The precursor of
miR-497 is located at a distance of w200 bases
upstream of miR-195 at chromosomal region 17p13.1,
suggesting that miR-497 and miR-195 belong to the
same miRNA cluster and are likely to be co-expressed.
We found that the expression of miR-195 was strongly
correlated with the miR-497 expression (corrZ0.9,
P!0.00001; Supplementary Figure 3, see section on
supplementary data given at the end of this article).
Effect of altered miR-483, miR-195, and miR-497
expression on cell proliferation and apoptosis
in NCI-H295R cells
We further evaluated the functional consequences from
dysregulation of four miRNAs in human NCI-H295R
ACC cells. These miRNAs were chosen because of
their associations with malignancy in adrenal cortical
tumors. In Fig. 3A, inhibition of miR-483-3p or
miR-483-5p expression resulted in signiﬁcant
reduction (20 and 30% respectively), of cell prolifer-
ation compared with negative control cells (treated
with anti-miR-negative control #1). In addition,
cells transfected with anti-miR-483-3p, but not with
anti-miR-483-5p, showed a signiﬁcant increase
(approximately twofold) in apoptosis compared with
cells transfected with negative control (Fig. 3A).
We also explored the functional consequences of
miR-497 and miR-195 overexpression, which were
found signiﬁcantly downregulated in ACC compared
with adenomas. In line with the effects observed for
miR-483-3p, overexpression of miR-195 or miR-497
led to a signiﬁcant decrease in cell growth (30 and 40%
respectively), and a concomitant induction of cell
death (40 and 30% respectively), compared with
negative control (Fig. 3B).
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Figure 2 Relative expression levels of miR-483-3p, miR-483-5p, miR-210, miR-21, miR-195, miR-497, and miR-1974 in the different
sample groups. Box plots show miRNA expression levels determined by qRT-PCR in adrenocortical carcinomas, adenomas, and
adrenal cortices. Statistical signiﬁcances between the groups were determined with two-tailed unpaired t-test and P!0.05 were
considered signiﬁcant.
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expression in adrenocortical tumors
Recent ﬁndings of the pro-apoptotic gene
BBC3/PUMA as a direct target of miR-483-3p
(Veronese et al. 2010), in combination with our
observations of the pro-apoptotic and anti-proliferative
effects of miR-483-3p silencing, prompted us to
investigate a possible connection between PUMA and
miR-483-3p expression in adrenocortical tumors.
We measured the PUMA protein expression levels by
western blot analysis in three normal adrenal cortical
samples, 26 adenomas, and 22 carcinomas, and
compared with the expression of miR-483-3p.I n
Fig. 4, high levels of PUMA expression were detected
in almost all adenomas and adrenal cortices, but only
in a small proportion of carcinomas. The PUMA
protein expression was inversely correlated with the
miR-483-3p expression (corrZK0.31, PZ0.025).
Notably, those carcinomas expressing low levels of
miR-483-3p had a higher PUMA protein expression
(e.g. Ca 20), and vice versa (e.g. Ca 6; Fig. 4).
miRNAs associated with survival of ACC patients
In an attempt to identify speciﬁc miRNAs associated
with survival, we performed SAM survival analysis on
the carcinoma cases. The analysis identiﬁed 11
miRNAs that could predict the disease outcome with
a SAM survival score O2.6 (FDR: 0%; Fig. 5A).
Speciﬁcally high expression of miR-638, miR-1246,
miR-1915, miR-1275, miR-503, miR-671-5p, miR-
1268, miR-762, miR-331-3p, miR-1202, and miR-572
were found associated with short survival (Fig. 5A).
Although two of the carcinoma cases (Ca 23 and Ca
24) had a shorter follow-up (25 and 20 months
respectively), exclusion of these cases from the
survival analyses did not affect the signiﬁcance of
our results. Using the miRNA set selected by
SAM survival analysis, we performed a hierarchical
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classiﬁed into three clusters. As shown in Fig. 5A, the
survival analysis revealed a signiﬁcant difference
between cluster 3 and the other two clusters
(PZ0.03, log-rank test). Furthermore, using Kaplan–
Meier survival and log-rank analyses, we evaluated the
association with survival for each individual miRNA
detected by SAM. The analysis revealed six of these 11
miRNAs as signiﬁcantly associated with survival
(Supplementary Figure 4, see section on supple-
mentary data given at the end of this article). High
expression of miR-503 (P!0.001; log-rank test), miR-
1202 (PZ0.009), miR-1915 (PZ0.013), miR-638
(PZ0.018), miR-572 (PZ0.024), and miR-1275
(PZ0.035) were signiﬁcantly associated with shorter
overall survival (Supplementary Figure 4).
To validate the signiﬁcance of these prognostic
miRNAs, we evaluated the expression of six miRNAs
in the cohort of 25 ACC by qRT-PCR. Using Kaplan–
Meier survival curves and log-rank analysis, we
conﬁrmed the signiﬁcant association of miR-503
(PZ0.006), miR-1202 (PZ0.005), and miR-1275
(PZ0.042) with overall survival (Fig. 5B), which is
in concordance with the array-based results. However,
miR-572, miR-1915, and miR-638 were not found
statistically signiﬁcant (data not shown).
Discussion
In this study, we identiﬁed a set of miRNAs that is
differentially expressed between malignant and non-
malignant samples, and a small number of miRNAs
associated with survival in ACC patients.
miRNA deregulation in ACC
Using a microarray approach, we identiﬁed distinct
miRNA expression patterns between carcinoma and
non-carcinoma samples. The consistency of the
ﬁndings was supported by the validation of seven of
the most signiﬁcant differentially expressed miRNAs
in an extended series of adrenocortical tumors by
TaqMan qRT-PCR methodology. Taken together, the
observations indicate the signiﬁcant importance of
these miRNAs in the pathogenesis of ACC.
We showed that miR-497 expression is signiﬁcantly
reduced in ACC compared with adenomas. In con-
cordance with our results, miR-497 was reported
underexpressed in childhood adrenocortical tumors
(Doghman et al. 2010). Decreased expression of
miR-497hasalsobeenobservedinperitonealcarcinoma
(Flavin et al. 2009) and male breast cancer (Lehmann
et al.2 0 1 0 ). Downregulation of miR-195 was recently
reported in adult ACC (Soon et al. 2009b), which is
consistent with our results. The precursors of miR-497
andmiR-195arelikelygeneratedfromthesamemiRNA
cluster because of their close proximity in genomic
location.AstrongpositivecorrelationbetweenmiR-497
and miR-195 expressions also indicates that these
two miRNAs were co-expressed. The co-expression
ofthemiR-497–195clustersuggeststhatthesemiRNAs
could be co-regulated by common transcriptional
factor(s) and they may have some common functions.
Although the factor(s) regulating the transcription of
this miRNA cluster are yet unknown, a common
deletion within this chromosomal region (17p13)
has been reported in ACC (Kjellman et al. 1996,
Soon et al.2 0 0 8 ), but not in benign adrenocortical
conditions (Almeida et al. 2011). This may, at least in
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cluster in ACC.
Despite the expression association, functional roles
of miRNAs in ACC cells remain uncharacterized. In
this study, we demonstrate the functional role of
deregulated miRNAs in ACC cells using experimental
cell culture systems. Overexpression of miR-195 or
miR-497 in the NCI-H295R human ACC cell line
could signiﬁcantly reduce cell proliferation in com-
bination with a pro-apoptotic effect. Consistent with
our ﬁndings, miR-497 was previously shown to
promote neural death by negatively regulating
expression of anti-apoptotic proteins, bcl-2 and bcl-w
(Yin et al. 2010). Moreover, overexpression of
miR-195 could induce cell cycle arrest in hepatocel-
lular carcinoma cells (Xu et al. 2009) and promote cell
apoptosis in human colorectal cancer cells (Liu et al.
2010). Taken together, these ﬁndings revealed the
potential tumor suppressive role and pro-apoptotic
activity of this miRNA cluster in ACC and other cell
types. Further investigation is certainly warranted to
identify their potential targets and elucidate their
mechanisms of action in ACC development.
We also demonstrated that miR-483-3p and
miR-483-5p expression levels were signiﬁcantly
higher in carcinomas compared with the benign or
normal counterparts. Concordantly, overexpression of
miR-483-3p and miR-483-5p were recently reported
in childhood adrenocortical tumors (Doghman et al.
2010) and adult ACC (Patterson et al. 2011)
respectively. However, Soon et al. (2009b) observed
a non-signiﬁcant trend for miR-483 overexpression
in adult ACC versus adenomas, where the lack of
statistical signiﬁcance could result from the relatively
limited sample size. miR-483-3p and miR-483-5p are
derived from different arms (30 and 50 arms respec-
tively), of the same miRNA precursor. Although
both miR-483-3p and miR-483-5p were signiﬁcantly
upregulated in carcinomas, we noted that the 30-strand
was much more abundant than the 50-strand.
Overexpression of miR-483-3p may be a common
alteration of tumor cells in several different tumor
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483-3p has also been demonstrated in Wilms’ tumors,
and in colon, breast, and liver cancers (Veronese et al.
2010). Importantly, Veronese et al. (2010) recently
demonstrated that silencing of miR-483-3p could
suppress cell proliferation and induce apoptosis in the
hepatocarcinoma cell line HepG2, as well as inhibit
tumorigenicity in vivo. In line with their ﬁndings,
we also observed a signiﬁcant decrease in cell
proliferation and increase in apoptosis by suppressing
miR-483-3p expression in the human ACC cell line
NCI-H295R. PUMA was identiﬁed as a target of
miR-483-3p (Veronese et al. 2010). We also observed
a signiﬁcant inverse correlation between PUMA pro-
tein expression and miR-483-3p expression levels in
ACC. The data support the expected inverse relation-
ship between miRNA and target gene expressions.
miR-483-5p overexpression has been reported in
tumors of the adrenal gland, such as ACC (Patterson
et al. 2011) and pheochromocytoma (Meyer-Rochow
et al. 2010). Although Ma et al. (2011) recently
demonstrated that miR-483-5p directly targets Socs3
in the mouse hepatoma Hepa 1–6 cells, its function
remains uncharacterized. In this study, we show that
miR-483-5p also promotes cell proliferation but has
no effect on apoptosis in NCI-H295R ACC cells.
The differential effect on apoptosis by miR-483-3p
and miR-483-5p may be related to the pro-apoptotic
PUMA. While PUMA is a target of miR-483-3p,
computational prediction and expression correlation
between miR-483-5p and PUMA expression (data
not shown) suggest that PUMA is not a target of
miR-483-5p. Taken together, miR-483 is involved in
various cancer types and miR-483-3p plays an
important role in anti-apoptotic protection.
In addition, we also observed a signiﬁcantly
increased expression of miR-21 and miR-210 in ACC
compared with adenomas and adrenal cortices. Over-
expression of miR-21 has been reported in several
tumor types, such as glioblastoma (Chan et al. 2005),
breast cancer (Iorio et al. 2005, Yan et al. 2008),
chronic lymphocytic leukemia (Fulci et al. 2007), and
cervical cancer (Lui et al. 2007). Several studies also
showed that miR-21 knockdown could impair cell
growth, induce apoptosis and interfere with cell
migration and invasion of cancer cells (Chan et al.
2005, Si et al. 2007, Asangani et al. 2008, Zhu et al.
2008). Although overexpression of miR-21 has not
been reported in previous miRNA proﬁling studies of
ACC (Soon et al. 2009b, Tombol et al. 2009, Doghman
et al. 2010, Patterson et al. 2011), its upregulation has
been shown to promote cell proliferation in human
NCI-H295R ACC cells (Romero et al. 2008). These
lines of evidence suggest that miR-21 plays a common
oncogenic role in several tumor types, including ACC.
Overexpression of miR-210 appears to be a common
feature in many tumor types (Camps et al. 2008, Huang
et al. 2009, Zhang et al. 2009, Greither et al. 2010)
and several reports have shown that its expression is
regulated by hypoxia-inducible factor 1a (HIF1a).
Hypoxia is frequently found in tumors and is asso-
ciated with radiation-resistance and chemotherapy-
resistance, increased metastatic potential and poor
outcome (Pouyssegur et al. 2006, Lee et al. 2007).
However, virtually no studies have so far been reported
that evaluate the role of hypoxia in the pathogenesis
of ACC. Further investigations are warranted to
determine the involvement of hypoxia and the role
of miR-210 in ACC development or progression.
miRNAs associated with survival in ACC
Recently, Soon et al. (2009b) identiﬁed two miRNAs
(i.e. miR-483-5p and miR-195) associated with survival
in ACC using Exiqon miRCURY LNA microarray,
however these miRNAs were not signiﬁcantly associ-
ated with survival in our cohort using both Agilent
microarray and qRT-PCR methods (data not shown).
The discrepancy could be due to differences in sample
characteristics, platforms, and data analysis methods.
In this study, we demonstrate that ACC can be
divided into different subgroups with different clinical
outcomes based on their miRNA expression proﬁles.
Cluster 3 is associated with poorer outcome, in which
most patients were died of the disease. The overall
survival is apparently better in the other two clusters
in which most patients are still alive. However, no
distinct histologic features were found between the
two subgroups (data not shown). Survival analysis
revealed that high expression of miR-503, miR-1202,
and miR-1275 are signiﬁcantly associated with
poor survival of ACC patients. Notably, increased
expression of miR-503 has been observed in various
human tumors, including parathyroid carcinoma
(Corbetta et al. 2010), retinoblastoma (Zhao et al.
2009), and ACC (Soon et al. 2009b, Tombol et al.
2009). However, to our knowledge, the association
between miR-503 expression and survival has not been
reported in any cancer type. Functionally, miR-503
has been shown to directly target cell cycle regulators,
which leads to induction of G1 cell cycle arrest in
various cancer cell lines and promotion of cell
differentiation in monocytes and myoblasts (Forrest
et al. 2010, Sarkar et al. 2010). Although miR-503 is
important for promoting cell cycle arrest and differen-
tiation, its role in tumor progression has yet to be
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signiﬁcant association with survival, miR-1202 and
miR-1275, have not been described in any cancer types.
Nothing is known about their expression levels and
function.
In conclusion, our ﬁndings show deregulation of a
subset of miRNAs in ACC together with a potential
role of miR-483, miR-195,a n dmiR-497 in the
pathogenesis of this neoplasm. Our study also reveals
that high expression of miR-503, miR-1202,a n d
miR-1275 are associated with poor survival of ACC
patients, suggesting their potential prognostic value
in ACC.
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